Delayed-release Multi Matrix System (MMX™) mesalazine: In ulcerative colitis

Drugs

Volumn 67, Issue 17, 2007, Pages 2635-2642

  McCormack, Paul L ^a   Robinson, Dean M ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Controlled release drugs; Mesalazine, general; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; LIALDA; MESALAZINE; MESAVANCOL; MEZAVANT; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COLON MUCOSA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FLATULENCE; HUMAN; INFLAMMATION; PANCREATITIS; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; ULCERATIVE COLITIS;

EID: 36348930927     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767170-00010     Document Type: Review

References (21)

1. Ardizzone S, Bianchi Porro G. A practical guide to the management of distal ulcerative colitis. Drugs 1998 Apr; 55 (4): 519-42
2. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 Aug 1; 24 (3): 465-74
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 Jul; 99 (7): 1371-85
4. Shire PLC. FDA approves LIALDA™ (mesalamine), the first oral once-daily mesalamine for patients with active, mild to moderate ulcerative colitis [media release]. 2007 Jan 16
5. LIALDA™ (mesalamine) delayed release tablets: US prescrib-ing information. Wayne (PA): Shire US Inc., 2007
6. Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999 Mar; 57 (3): 383-408
7. Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 2000 Apr; 59 (4): 929-56
8. Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000 Dec; 95 (12): 3452-7
9. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006 Oct 1; 24 (7): 1087-97
10. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005 May; 11 (5): 421-7
11. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 Jan; 5 (1): 95-102
12. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 Jan; 132 (1): 66-75
13. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. International study group. BMJ 1989 Jan 14; 298 (6666): 82-6
14. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987 Jun; 92 (6): 1894-8
15. Fĺoren CH, Benoni C, Wilĺen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987 May; 22 (4): 459-62
16. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007 Jul 15; 26 (2): 205-15
17. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. SPD476, a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are witched from low-dose oral 5-ASA therapy or are 5-ASA naive: an analysis of pooled data from two phase III studies [abstract no. T1139]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): A-482
18. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-sided and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled phase III studies [abstract no. T1148]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): A-484
19. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. Once- and twice-daily Spd476, a novel, high-strength formulation of 5-ASA, induces remission of both mild and moderate ulcerative colitis: a prespecified analysis of combined data from two pivotal, randomized, placebo-controlled, phase III studies [abstract no. T1147]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): A-484
20. Giuliani SpA. US FDA approves Shire's Lialda® for the induction of remission in patients with ulcerative colitis. [media release]. 2007 Jan 18
21. Shire PLC. Shire receives label agreement in Europe for ulcerative colitis treatment, Mezavant™(mesalazine) [media release]. 2006 Dec 14